GSK specialty medicines sales rise 15% as £328m restructuring charge weakens reported profit

GSK plc (LSE: GSK; NYSE: GSK) reported third-quarter 2026 revenue of £8.89 billion, representing 5% growth at constant exchange rates, as specialty medicines sales increased 15% and newer products supported demand across several therapeutic areas. Core operating profit increased 5% in constant currency to £3.08 billion, while statutory operating profit declined 16% on the same basis to £2.13 billion. The October 28 results included £328 million in restructuring charges associated with GSK’s Accelerate Growth programme, illustrating the financial cost of reorganising the pharmaceutical business. Management maintained its annual guidance and a longer-term ambition to generate more than £40 billion in revenue by 2031, despite continuing weakness in several vaccine products and the approaching loss of exclusivity for important HIV medicines.

The results highlight the transformation GSK is pursuing under Chief Executive Officer Luke Miels. The company is investing in specialty medicines and expanding its research portfolio across oncology, infectious diseases and immunology while working to improve productivity. New approvals and clinical developments provide additional growth opportunities, but the financial benefits will depend on regulatory decisions, market adoption and the cost of developing medicines.

The most important commercial distinction is between GSK’s faster-growing specialty medicines and its vaccine portfolio. HIV, respiratory, immunology and oncology products generated strong sales growth, while vaccines revenue declined and demand for certain established brands remained weak. The company must maintain that balance while preparing for patent expiries that could materially affect revenue later in the decade.

Why are GSK’s specialty medicines growing faster than the wider pharmaceutical business?

Specialty Medicines generated approximately £3.9 billion during the third quarter, representing 15% growth at constant exchange rates. The division accounted for a substantial proportion of GSK’s consolidated revenue and provided the strongest growth among its major reporting categories. The performance was supported by demand across HIV, respiratory, immunology and oncology medicines.

HIV revenue increased approximately 10% to £2.1 billion, demonstrating the commercial importance of GSK’s established treatment portfolio. Respiratory, Immunology and Inflammation sales reached approximately £1.1 billion, representing 21% growth, while oncology increased 23% to approximately £600 million. These categories have different customer populations and treatment requirements, providing diversification within the faster-growing part of the business.

Specialty medicines can support attractive margins when products offer differentiated clinical benefits and retain appropriate market access. However, reimbursement, competition and regulatory restrictions influence the commercial value of individual treatments. Revenue growth also requires ongoing investment in clinical development and product launches.

GSK’s strategy increasingly depends on replacing mature products with newer medicines capable of generating sustained revenue. Success requires both scientific progress and effective commercial execution, particularly when patients have established treatment alternatives. The strong quarter provides encouragement but does not guarantee that every new product will achieve comparable growth.

The financial value of the expansion will depend on margins and cash generation as well as sales. The company must continue funding research while managing the commercial costs of entering additional markets. A strong product portfolio can support long-term growth only when those investments generate adequate returns.

Why are Shingrix and Arexvy creating pressure within GSK’s vaccines portfolio?

Vaccines revenue declined approximately 2% to £2.6 billion in constant currencies, contrasting with the double-digit growth achieved in Specialty Medicines. Shingrix generated approximately £800 million, representing a 5% decline, while Arexvy revenue fell 24% to approximately £200 million. Meningitis vaccines provided a more encouraging result, increasing 12% to roughly £600 million.

The differences reflect varying demand conditions across established vaccine products. Vaccine uptake depends on eligibility, public health recommendations, reimbursement, healthcare access and consumer awareness. A commercially successful product may still experience lower sales when vaccination campaigns mature or purchasing schedules change.

Shingrix remains an important franchise in protection against shingles, but its revenue can vary with regional vaccination activity and the timing of public health programmes. Arexvy faces a market where recommendations and eligible populations influence commercial demand. These conditions differ from the recurring prescription patterns associated with medicines used to treat chronic diseases.

GSK received Japanese regulatory approval for a pre-filled syringe presentation of Shingrix, potentially simplifying administration. The development may improve convenience for healthcare providers, but it does not automatically establish a material increase in future sales. Adoption will depend on clinical practice, procurement and market conditions.

The company must also continue developing new vaccine opportunities. Its seasonal influenza programme has entered Phase III testing using an mRNA-based candidate, following earlier positive clinical results. However, successful earlier studies do not guarantee that the investigational vaccine will achieve approval or commercial adoption.

The financial challenge is maintaining vaccine profitability while supporting research and commercial investment. Stronger demand in selected products may offset weakness elsewhere, but the latest results demonstrate that the portfolio is not growing uniformly. Investors should assess individual product performance rather than rely exclusively on aggregate vaccine sales.

How did £328m in restructuring charges affect GSK’s reported operating profit?

GSK reported statutory operating profit of approximately £2.13 billion, representing a decline of 18% at actual exchange rates and 16% in constant currency. Core operating profit reached approximately £3.08 billion, increasing 3% at actual exchange rates and 5% in constant currency. The distinction reflects expenses excluded under the company’s core financial reporting methodology.

The quarter included approximately £328 million in major restructuring charges related to the Accelerate Growth programme. These costs represent the financial requirements of changing the company’s operating structure and investment priorities. Management expects the programme to support efficiency over time, but its immediate costs remain economically relevant.

Statutory earnings per share declined to 38.5 pence from the year-earlier level, representing a 21% reduction in constant currency. Core earnings per share reached 54.6 pence, representing 1% growth in constant currency. The differences demonstrate how restructuring and other adjustments can affect the interpretation of profitability.

Investors should not treat adjusted earnings as identical to statutory profit. Alternative measures can help assess the performance of continuing operations, but recurring restructuring expenditure would still affect cash generation and returns. The economic benefit will depend on whether GSK produces savings and stronger commercial performance after the initial costs are absorbed.

The company has been redirecting resources toward research programmes and commercial opportunities considered strategically important. This may improve long-term productivity, but the outcome depends on execution. Sustained margin improvement would provide stronger evidence of success than the announcement of restructuring targets alone.

Can new cancer medicine approvals support GSK’s long-term oncology ambitions?

GSK has reported several significant developments within its oncology portfolio, including regulatory approvals and positive clinical data for investigational medicines. The US Food and Drug Administration recently approved Jemperli for a specified population of adults with locally advanced rectal cancer involving mismatch repair deficiency or high microsatellite instability. The authorisation creates another potential commercial opportunity within a defined patient population.

The approval should not be interpreted as allowing unrestricted treatment of all colorectal or rectal cancers. Regulatory labels specify the relevant disease characteristics, treatment conditions and eligible patients. Commercial adoption will depend on clinical guidelines, physician decisions, reimbursement and the performance of available alternatives.

GSK also reported positive registrational data for Jideytro in first-line ROS1-positive non-small cell lung cancer. The medicine had previously received US approval for a different treatment setting, but the new trial results do not themselves establish approval for the first-line indication. A separate regulatory process is required before an expanded label can be assumed.

The company is developing additional oncology candidates, including programmes referred to as Ris-Rez and Mo-Rez. Early clinical findings may provide valuable scientific evidence, but the commercial significance remains uncertain until appropriate trials are completed. GSK must evaluate safety, efficacy and the comparative benefits of each programme.

Oncology offers significant commercial opportunities, but it is also a competitive field with complex development requirements. Medicines targeting specific biological characteristics may serve comparatively narrow patient populations. Their financial value depends on clinical differentiation, eligible patient numbers and market access.

The stronger oncology sales recorded during the quarter support management’s strategy, but the future portfolio remains exposed to development risks. Investors should distinguish approved products generating revenue from investigational medicines whose clinical and regulatory outcomes are uncertain. That distinction is essential to assessing the credibility of long-term growth expectations.

Why is GSK investing heavily in its research pipeline before HIV patent expiries?

GSK has identified the approaching loss of exclusivity for dolutegravir-related products during the 2028 to 2030 period as an important challenge. Patent expiries and related competition can reduce the pricing power and sales of established medicines. The company must therefore generate sufficient growth from other products to offset the financial pressure.

Management expects its operating margin to remain stable or improve through the relevant loss-of-exclusivity period. However, that is a forward-looking objective dependent on product performance, efficiency improvements and the pace of competitive entry. The financial consequences could differ if replacement medicines grow more slowly than expected.

The company’s research programme is expanding, with 18 Phase III trial starts achieved during 2026 against a target of 22. Late-stage trials require considerable expenditure and can involve lengthy periods before regulatory decisions. Successful programmes may create substantial commercial opportunities, but failures can alter expected returns.

GSK recently received approval for Hibsago in the United States and Japan for chronic hepatitis B under the relevant regulatory indications. The medicine represents a potentially important addition to its infectious disease portfolio, although market adoption and real-world treatment outcomes will determine the eventual contribution. Regulatory approval should not be treated as proof that the product will generate a particular revenue amount.

The company is also investing in respiratory, immunology and oncology programmes intended to diversify future sales. This broad approach can reduce reliance on one therapeutic franchise, but it also increases the complexity of capital allocation. Management must decide which programmes justify continued development as new clinical evidence emerges.

What does the unchanged 2026 guidance reveal about GSK’s confidence in the transformation?

GSK maintained its full-year revenue growth guidance of between 3% and 5% at constant exchange rates. Management also expects core operating profit growth between 7% and 9% and core earnings per share growth within the same range. The unchanged outlook suggests confidence in the current commercial performance while recognising ongoing investment and restructuring costs.

The company reported cash generated from operations of approximately £3.12 billion during the third quarter, representing 24% growth. Free cash flow reached approximately £2.1 billion, supporting investment and shareholder distributions. These figures provide evidence of financial capacity, although future cash generation will depend on product sales and expenditure.

Management declared a quarterly dividend of 17 pence per share and expects a total dividend of 70 pence for 2026. The distribution demonstrates a continuing commitment to shareholder returns while funding research and restructuring. However, sustaining dividend growth will require reliable cash generation and disciplined investment.

GSK’s longer-term goal is to exceed £40 billion in annual sales by 2031. Achieving that objective will require strong growth from specialty medicines, successful pipeline development and effective management of mature products. The target represents an ambition rather than guaranteed future revenue.

The company’s operating performance currently supports the strategy, but the statutory earnings decline demonstrates the financial cost of transformation. Investors should monitor the relationship between restructuring expenditure, recurring savings and the profitability of newer products. The progress of major clinical programmes will also influence confidence in the longer-term forecast.

Can GSK’s specialty medicine momentum offset vaccine weakness and future generic competition?

GSK’s third-quarter results provide encouraging evidence that specialty medicines are becoming a stronger source of growth. HIV, respiratory, immunology and oncology sales expanded, while several new regulatory approvals and clinical developments strengthened the potential product pipeline. However, vaccines remained weaker, and the company continues facing the challenge of protecting revenue from established medicines.

The core operating business is generating profit and cash flow, but restructuring costs and additional research investment are affecting statutory earnings. This distinction matters because investors ultimately require returns from the transformation after accounting for the expenditure needed to achieve it. A sustained improvement in both core and reported profitability would strengthen the investment case.

The next important indicators will include specialty medicine sales, Shingrix and Arexvy demand, clinical programme milestones and restructuring-related costs. Investors should also assess whether new products can generate sufficient commercial revenue before the more significant HIV patent expiries arrive. A broad research pipeline provides opportunities but does not eliminate development uncertainty.

GSK’s October results show a pharmaceutical group making progress towards a more diversified and research-led business. The strategy has meaningful commercial support, particularly in specialty medicines, but its financial success remains conditional on clinical execution and operating efficiency. The decisive question is whether these investments can sustain earnings growth as older products lose competitive protection.